Navigation Links
Regenative Labs Receives First National Medicare/Medicaid Insurance Reimbursement Approval for Wharton’s Jelly Allografts

Regenative Labs has received approval from the Centers for Medicare & Medicaid Services (CMS) to cover two new innovations, CoreText™ and ProText™, making them the first Wharton’s jelly allografts to be assigned a Q code and be approved for application directly to a defect using a syringe. The company’s solutions are the first Wharton’s jelly allograft product to be recognized as a 361 HCT/P by CMS regulated under 21CFR 1271.10, establishing a new Level II HCPCS code Q4246 “CoreText or ProText, per cc.”

For decades, millions of Americans struggling with intense pain, discomfort, and mobility issues, have had few choices other than pain numbing drugs like opiates. CoreText™ and ProText™ are the first Wharton’s jelly tissue products approved by CMS for application directly to the defect – or injured area – “using a syringe.” With today’s announcement, CMS recognizes these two exclusive healthcare products as appropriate to regulate solely under Section 361 of the Public Health Service Act, as these products meet the following four criteria: they are minimally manipulated; they are intended for homologous use; they do not involve a combination of cells and tissues with another article (with some limited exceptions); and they do not have a systemic effect and are not dependent upon the metabolic activity of living cells for its primary function [as per the July 2020 guidelines 21CFR Part 1271.10(a)].

The tissue allograft products from Regenative Labs, derived from Wharton’s jelly, are available now and more than 500 physicians nationwide are already using the products to improve the quality of life for their patients. Now, Medicare and Medicaid patients can receive insurance reimbursement for care incorporating these products.

“We work with dermatologists, diabetic specialists, orthopedists, surgeons, sports medicine physicians, and others to address the connective tissue supplementation needs of their patients,” said Tyler Barrett, CEO of Regenative Labs. “We proudly strive to provide the highest quality of tissue allografts available and we’re excited that this level of medicine will be available now to the public more widely with the recent CMS decision regarding insurance coverage.”

According to CMS, both the products are intended to provide the extracellular matrix needed for the infiltration, attachment, and proliferation of cells required for the repair of damaged tissue. They are typically used for muscle and cartilage tears and to help repair damaged tissue. The products are used for wounds and tissue defects, and are applied directly to the defect using a syringe.

ProText™ is the most concentrated Wharton’s jelly product of the two Regenative Labs solutions. Less invasive than other treatments like PRP, bone marrow aspiration, or adipose tissue extraction, ProText™ is regulated as a human cell, tissue, or cellular tissue-based product (HCT/P under 21CFR Part 1271 and Section 361 of the Public Health Service Act.)

CoreText™ is a minimally manipulated Wharton’s jelly, rich in cytokines, growth factors, and proteins. Less invasive than adipose tissue extraction and bone marrow aspiration, CoreText™ treatments result in less time-consuming procedures and, more importantly, less pain.

Regenative Labs developed CoreText™ and ProText™ in 2018 and launched the products in 2019 which are being used in about 500 clinics nationwide. CMS covers patients in their 60s and older with the most common ailments including large joints like knees, hips, and shoulders. Health conscious persons in their 40s and 50s interested in preventing future debilitating issues and supplementing other treatments are also good candidates for these products, and Regenative Labs encourages people to act early. Regenative Labs has always been one of the lowest cost providers of homologous use tissue products in hopes that these savings will carry over to the patient.

For more information, visit

About Regenative Labs
Regenative Labs produces regenerative medicine products to address the root cause of a patient’s conditions using Wharton’s jelly innovations rather than mask the pain with other treatments. Regenative Labs works closely with scientists, physicians, hospitals, and surgery centers to constantly monitor and improve patient progress and outcomes for new product development. Formed by veteran industry professionals familiar with the daily challenges of innovations in healthcare, the company provides effective, non-addictive, non-invasive options for patients. Regenative Labs has a laser-focused, expert product research and development team which follows FDA guidelines of minimal manipulation for homologous use. The company adheres to AATB and FDA guidelines. Learn more at

# # #

Read the full story at

Source: PRWeb
Copyright©2020 Vocus, Inc.
All rights reserved

Related biology news :

1. Noblis Receives U.S. Patent for SNP Analysis and Genome Sequencing System and Methods
2. Fluxion Biosciences Receives National Cancer Institute Grant for Development of ERASE-Seq Liquid Biopsy Technology
3. Catalent Receives P&G External Business Partner of the Year Award
4. rHEALTH Technology Receives Notice of Allowance from US Patent Office for Multiplexed Tests in Small Sample Volumes
5. uBiome Receives Patent for Microbiome-Derived Diagnostics and Therapeutics for Immune-Microbial Dysfunction
6. NDA Partners Expert Consultant Vinod Shah, PhD, Receives AAPS Award for Global Leadership
7. EARTHRES Vice President Louis F. Vittorio, Jr., P.G., Receives IBWA Advocacy Award
8. FebriDx® Receives Updated CE Mark to Allow Incorporation of All-in-One Test Format
9. Captiva Spine Receives Clearance to Market TowerLOX-EXT MIS Extended Tab Pedicle Screw
10. EyeLock Receives Patent for Sequentially Linking Iris Matching With Facial Imaging
11. Genos receives CAP Accreditation for Meeting the Highest Standards in Laboratory Practices
Post Your Comments:
(Date:7/31/2020)... ... July 30, 2020 , ... Justin Zamirowski to lead ... near term focus on Type 2 diabetes and associated comorbidities. , Justin brings ... areas and classes. As Chief Commercial Officer, Justin will lead Better Therapeutics’ ...
(Date:7/10/2020)... ... July 09, 2020 , ... Today CJ BIO announced the first in a ... the “fifth taste” phenomenon that is revolutionizing ingredient mixes, nutritional content and flavor profiles ... on Monday, July 13, 2020 at11:00 AM (CDT) during SHIFT20, the virtual edition of ...
(Date:7/1/2020)... ... July 01, 2020 , ... Cure ... for glioblastoma—the most common and aggressive adult brain cancer—announced today the appointments of ... Fellows are charged with supporting the organization’s initiatives and overall vision. , "Senior ...
Breaking Biology News(10 mins):
(Date:8/3/2020)... ... , ... ERT, the global leader in clinical ... one of the 100 most inspiring individuals in the life-sciences industry by PharmaVoice. ... on how they have inspired their colleagues and affected positive changes in their ...
(Date:7/31/2020)... ... 2020 , ... Diversified Technologies, Inc. has introduced a full ... drive Klystrons, TWTs, IOTs, and magnetrons. , DTI Radar Transmitter Systems ... push-pull configuration; yielding fast fall time for a capacitive load. These all solid-state ...
(Date:7/31/2020)... ... , ... The SDX® Respiratory Gating System , trusted ... its 20th anniversary of worldwide use. Introduced in the US over the past ... of Pennsylvania, University of Michigan, University of Maryland, University of California San Francisco—and ...
(Date:7/18/2020)... ... July 16, 2020 , ... “We are thrilled to deliver this new ... only technology of its kind on the market and we were pleased that the ... capacity of traditional cultured ingredients, creating a natural way to extend the shelf life ...
Breaking Biology Technology: